Acarbose for Secondary Prevention of Cardiovascular Events in Patients With Coronary Stenting and Abnormal Glucose Tolerance
- Conditions
- Abnormal Glucose Tolerance
- Registration Number
- JPRN-C000000140
- Lead Sponsor
- Institute of Biomedical Research and Innovation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 300
Not provided
1)Patients with abnormal glucose tolerance caused by other organic disorders such as pancreatitis, hemochromatosis, post pancreatectomy, hyperthyroidism, Cushing syndrome, Prader-Willi syndrome etc. 2)Patients with planned angioplasty. 3)Patients with uncontrollable congestive heart failure. 4)Less than 6 months since last episode of cerebral infarction. 5)Patients who have received medication for diabetes mellitus before. 6)AST(GOT) exceeding 100 IU/L or ALT(GPT) exceeding 100 IU/L. 7)Creatinine exceeding 2mg/dl. 8)Patients with a history of ileus or less than 6 months since celiotomy. 9)Pregnant women or those who plan pregnancy, or are in the lactation period. 10)Habitual drinker (more than 100ml/day of alcohol). 11)Patients with a history of gastrectomy. 12)Patients for whom it is impossible to follow up for 5 years. 13)Any other reason that the clinical supervisors or clinical researchers may have for considering a case unsuitable for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiovascular event free survival time
- Secondary Outcome Measures
Name Time Method 1)Conversion of abnormal glucose tolerance to type 2 diabetes 2)All cause of death 3)Occurrence of every cardiovascular event 4)Occurrence of in-stent restenosis 5)Regression of intimal plus medial complex of the carotid artery 6)Change in fasting, 2-hour blood glucose and insulin level 7)Change in homeostatis model assessment of insulin resistance 8)Change in HbA1c 9)Change in lipid profile 10)Change in high sensitive CRP 11)Change in Body Mass Index and body weight